RA patients treated with baricitinib reported greater improvements in pain compared with adalimumab

5 Nov 2017

Post-hoc analysis shows pain improvement was consistent regardless of a patient's baseline pain severity.

Eli Lilly and Incyte Corporation have announced that patients with moderate-to-severe rheumatoid arthritis (RA) treated with baricitinib reported greater improvements in pain control when compared to Humira (adalimumab) or placebo. A new post-hoc analysis of the Phase III RA-BEAM study disclosing outcomes of patient-reported levels of pain control was presented at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in San Diego, California.

RA patients treated with baricitinib reported greater improvements in pain compared with adalimumab

"While there are many treatments available for RA patients, these data suggest that baricitinib, if approved, may be an important advancement for patients suffering from RA-related pain," said James McGill, distinguished medical fellow and global brand development leader, Lilly Bio-Medicines. "We are pleased to share these data suggesting that baricitinib could provide a potential new option for people living with RA. We remain committed to making life better for people with rheumatoid arthritis and improving patient care."

RA-BEAM was a 52-week trial of 1,305 patients who had active, moderate-to-severe RA, despite ongoing treatment with methotrexate. Patients were randomized to placebo once daily, baricitinib 4 mg once daily or adalimumab 40 mg biweekly. All patients received background methotrexate. This post-hoc analysis reviewed outcomes of patient-reported levels of pain control during the first 24 weeks of the trial as measured by a 0-100 mm visual analog scale (VAS) during each study visit. Analyses were not adjusted for multiplicity, were exploratory in nature and further research should be conducted to confirm these results. Analysis of reduction in pain included an assessment of the time required to achieve ≥30%, ≥50% and ≥70% pain improvement, including the following results:

  • Patients treated with baricitinib reported 30% pain improvement at a median 1.9 weeks post-baseline, compared to adalimumab at a median 2 weeks and placebo at a median 4.6 weeks.
  • Patients treated with baricitinib reported 50% pain improvement at a median four weeks post-baseline, compared to adalimumab at a median 7.9 weeks and placebo at a median 14 weeks.
  • Patients treated with baricitinib reported 70% pain improvement at a median 12.4 weeks post-baseline, compared to adalimumab at a median 20 weeks and placebo at a median of greater than 24 weeks. From Week 24, non-rescued patients in the placebo group were switched to receive baricitinib.
  • For patients whose baseline pain levels were higher than the median, treatment with baricitinib also led to faster pain improvements than adalimumab or placebo.

    "Many RA patients continue to struggle with chronic pain," said Peter Taylor, presenting author and Professor at the University of Oxford. "These post-hoc analyses suggest that these RA patients may derive meaningful and consistent improvements in pain, particularly those patients with the highest pain at baseline."

    The observed safety profile in RA-BEAM was consistent with previous trials evaluating baricitinib. The percentage of patients stopping therapy due to adverse events through Week 24 were 3% in placebo, 5% in baricitinib and 2% in the adalimumab group. Serious adverse event rates through 24 weeks were similar with placebo and baricitinib (5% each) and lower with adalimumab (2%). No additional safety signals were observed during the post-hoc analysis.

    Lilly plans to resubmit the New Drug Application (NDA) with the FDA for baricitinib as a treatment for adult patients with RA before the end of January 2018. Baricitinib is approved for the treatment of adult patients with RA in several geographies, including the European Union and Japan.

    Read More

    Related tags

    Research & Development

    Related news

    Spanish CDMO working ahead of EU serialisation deadline

    Spanish CDMO working ahead of EU serialisation deadline

    6 Dec 2018

    Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.

    Read more 
    Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

    Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

    5 Dec 2018

    The financing will power the global commercial launch of the company's Fluidity One system.

    Read more 
    OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

    OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

    4 Dec 2018

    The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.

    Read more 
    NIH to evaluate effectiveness of male contraceptive skin gel

    NIH to evaluate effectiveness of male contraceptive skin gel

    28 Nov 2018

    The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.

    Read more 
    QPS expands US-based Phase I clinical trial capabilities

    QPS expands US-based Phase I clinical trial capabilities

    27 Nov 2018

    Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.

    Read more 
    Grant winners to investigate continuous manufacturing for gene therapies

    Grant winners to investigate continuous manufacturing for gene therapies

    26 Nov 2018

    Cobra Biologics, Pall, and the Cell and Gene Therapy Catapult share £1.5 million grant from the UK's innovation agency.

    Read more 
    Proprietary nasal delivery formulation of diazepam reaches NDA

    Proprietary nasal delivery formulation of diazepam reaches NDA

    7 Nov 2018

    The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

    Read more 
    Plasticell receives EU funding to advance neurodegenerative disease research

    Plasticell receives EU funding to advance neurodegenerative disease research

    1 Nov 2018

    Th company's CombiCult combinatorial cell culture technology will be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models.

    Read more 
    Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology

    Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology

    30 Oct 2018

    Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies.

    Read more 
    SIRIO Pharma opens multimillion gummy production plant

    SIRIO Pharma opens multimillion gummy production plant

    18 Oct 2018

    The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.

    Read more